Analyst coverage
| Firm | Analyst | Contact Information | Reports |
|---|---|---|---|
| Ascendiant | Keay Nakae |
949-259-4933 |
|
| Edison Research | John Savin |
+44 (0) 20-3077-5735 |
View Report
0.0 KB
|
| JMP Securities | Jason Butler |
212-906-3505 |
|
| Maxim | Jason Kolbert |
212-895-3516 |
|
| McNicoll, Lewis & Vlak LLC (MLV) | George Zavoico |
212-542-5877 |
|
| Medical Technology Stock Letter | John McCamant | ||
| Needham | Chad Messer |
212-705-0317 |
|
| Oppenheimer | Boris Peaker |
212-667-8564 |
|
| Roth Capital Partners | Joseph Pantginis |
646-358-1907 |
|
| Stifel Nicolaus Weisel | Stephen Willey |
212-271-3620 |
|
| WBB Securities, LLC | Steve Brozak |
908-518-7610 |
|
| Zacks Equity Research | Jason Napodano |
312- 265-9421 |
Zacks Initiation Report
367.0 KB
Q4 2010 Update
354.3 KB
RESTORE-CLI Update, November 19, 2010
342.3 KB
|
Aastrom Biosciences, Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Aastrom Biosciences, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aastrom Biosciences, Inc. or its management. Aastrom Biosciences, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
